Elixir Medical (Milpitas, Calif., and Tokyo) announced that its DynamX® Sirolimus-Eluting Coronary Bioadaptor System for the treatment of cor...
Novo Nordisk marked the beginning of its next chapter today by unveiling a rebrand centred on ‘Lasting Health Starts Now’, and the single &ls...
Technology transfer to LyFE Manufacturing Center™ completed following FDA review of improved manufacturing process and updated analytical methods...
Agreement includes pre-payment commitments for product sales and distribution of the second-generation multi-cytokine-based HCW11-006 for use as a reagen...
-Aptar Pharma, a global leader in drug delivery, dosing, protection technologies and services, today announced a collaboration with Aceso Therapeutics, a...
Early detection remains one of the biggest challenges in cancer care, particularly for ovarian cancer, where symptoms can be difficult to r...
Rezubio announced that it has successfully completed dosing of the first cohort in its Phase 1 clinical trial following clearances from the US FDA a...
Adds gildeuretinol (ALK-001), a differentiated Phase 3 oral investigational medicine designed to target the underlying biology of Stargardt’s disea...
Thryv Therapeutics Inc. ("Thryv"), a clinical-stage biopharmaceutical company advancing selective SGK1 inhibitors, announced that it has entered into an ...
Eisai Co., Ltd. and Biogen Inc. announced that the National Medical Products Administration (NMPA) of China has approved the subcutaneous formulation (su...
HUTCHMED (China) Limited announces positive high-level results from the SANOVO China Phase III trial in treatment-naïve patients with locally advanc...
Quoin Pharmaceuticals Ltd. (“Quoin” or the “Company”), a late clinical-stage specialty pharmaceutical company focused on rare and...
Roche announced that it has received FDA approval for expanded use of its PATHWAY® HER2 (4B5) and VENTANA® HER2 Dual ISH DNA Probe Coc...
Lexicon Pharmaceuticals, Inc. announced that it has earned a third $10 million milestone payment in 2026 from Novo Nordisk A/S following the achiev...
© 2026 Biopharma Boardroom. All Rights Reserved.
